The U.S. Food and Drug Administration (FDA) has given Intellia Therapeutics permission to open U.S. sites in its ongoing…
Articles by Marisa Wexler, MS
Astria Therapeutics has initiated a Phase 1b/2 trial called ALPHA-STAR to test STAR-0215, the company’s investigational therapy to prevent…
The first group of participants has been dosed in a Phase 1 clinical trial evaluating the safety and pharmacological properties…
NTLA-2002, an experimental gene-editing therapy for hereditary angioedema (HAE) being developed by Intellia Therapeutics, has been awarded…
Most hereditary angioedema (HAE) patients in a Phase 1/2 clinical trial have gone months without a swelling attack following…
People with hereditary angioedema (HAE) who switched to Orladeyo (berotralstat) from other preventive treatments generally experience a…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Takeda to extend the approval…
Japan’s Ministry of Health, Labour and Welfare has approved Berinert S.C. Injection 2000 — a C1-inhibitor replacement therapy designed to…
The European Patent Office has granted patent protection to Verseon covering the company’s experimental plasma kallikrein inhibitors (PKIs). Two of…
NTLA-2002, an experimental gene-editing therapy designed to prevent swelling attacks in people with hereditary angioedema (HAE), has been granted…